A Phase 4 interventional study of Lithium and Cariprazine in Depression, Bipolar, sponsored by Aalborg University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Aalborg University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing lithium in Bipolar Disorder — 1 open to participants now, 1 under way, none of them phase 3. Lithium · Bipolar Disorder.
Among the 37 studies testing lithium in Bipolar Disorder, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is one of 16 in phase 4, and was the 37th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →1 of the 37 studies testing lithium in Bipolar Disorder is open now, in 1 country.
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10 · Phase 4 16
First in 1994; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 122 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 49 across the 37 interventional studies. Of the 30 that completed or were terminated, 14 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 37 have an industry lead sponsor. The 10 most frequent:
Aalborg University Hospital is the lead sponsor of 199 studies on the registry; 42 are open to participants now.
Aalborg University Hospital has 1 study filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing lithium in Bipolar Disorder, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease.
The main question it aims to answer is:
Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6)
Participants will be randomized to treatment with either lithium or cariprazin.
The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version (HDS-6) from baseline to 8 weeks of treatment. Secondarily, we aimed at comparing the two study medications on various other clinically relevant variables.
These include depressive and manic symptomatology, sleep patterns, general well-being, cognitive function, social functioning and suicidal ideation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lithium citrate from 12 mmol increased to result in af 12-hour se-lithium between 0.6 and 0.8 mmol/l
Drug: Lithium
Cariprazine from 1.5 mg to 3 mg daily in a single dose.
Drug: Cariprazine
The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
Also known as: Litarex, ATC; N05AN01
The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Also known as: Reagila, ATC: N05AX15
Change in Hamilton Depressions scale, version 6 (HDS-6)
The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).
Time frame: 8 weeks
Difference-in-difference for HDS-17
Difference-in-differences for secondary continuous measures: Hamilton Depression Scale, 17 item version, HDS-17. (Values 0- 52, higher scores mean a worse outcome)
Time frame: Week 4 and 8
Difference-in-differences in HDS-6 for the PP 8 population
Difference-in-differences (baseline to 8 weeks) in HDS-6 for the PP 8 population. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).
Time frame: 8 weeks
Between-groups difference in proportion of responders and remitters in HDS-6 Scores.
Between-groups difference in proportion of responders and remitters at week 4 and 8 in HDS-6 scores. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).
Time frame: Week 4 and week 8
Between-groups difference in proportion of responders and remitters
Between-groups difference in proportion of responders and remitters with response and remission defined by HDS-6 score without clinical relevant manic symptoms (MAS \<7) at planned or premature endpoint. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Between-groups difference in the proportion of patients with 'acceptable wellbeing'
Between-groups difference in the proportion of patients with 'acceptable wellbeing', defined as the subject reporting ≥50 on the WHO-5 questionnaire at endpoint. WHO-five Well-being Index, WHO-5 (Values 0- 100, higher scores mean a better outcome).
Time frame: up to 8 weeks
Between-groups difference in proportion of switches to mania/hypomania.
Between-groups difference in proportion of switches to mania/hypomania with or without mixed features, defined as mania/hypomania after DSM-5 or symptoms requiring treatment (switch or response occurring at any time in the study period)
Time frame: up to 8 weeks
Between-groups difference in "(switch to mania or hypomania) / (response) -ratio",
Between-groups difference in "(switch to mania or hypomania) / (response) -ratio", defined as the number of subjects switching to mania or hypomania (as defined above) divided by the total number of responders, including those responders switching to mania
Time frame: up to 8 weeks
Between-group differences in reason for and time to all cause treatment discontinuation
Between-group differences in reason for and time to all cause treatment discontinuation (lack of effect, lack of tolerability, lost to follow-up, or other cause).
Time frame: up to 8 weeks
Between-group difference in treatment compliance.
Between-group difference in treatment compliance. Treatment compliance is defined as the proportion of received treatments out of the planned until drop-out or end of study.
Time frame: up to 8 weeks
Between-group difference in reasons for premature discontinuation
Between-group difference for the ITT population in reasons for premature discontinuation
Time frame: up to 8 weeks
Difference-in-difference for MAS
Difference-in-differences for secondary continuous measures: MAS Bech-Rafaelsens Mania scale .(Values 0- 44, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for MES
Difference-in-differences for secondary continuous measures: MES Bech-Rafaelsens Melancholia scale, MES .(Values 0- 44, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-differences for MADRS
Difference-in-differences for secondary continuous measures: MADRS Montgomery-Aaberg Depression Rating Scale, MADRS .(Values 0- 60, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for YMRS
Difference-in-differences for secondary continuous measures:YMRS Young Mania Rating Scale, YMRS .(Values 0- 60, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-differences for ASRM-14
Difference-in-differences for secondary continuous measures:ASRM-14 Altman Self-Rating Mania Scale-14, .(Values 0- 56, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-differences for MDI
Difference-in-differences for secondary continuous measures:MDI Major Depression Inventory, MDI (Values 0- 58, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-differences for WHO-5 questionnaire
Difference-in-differences for secondary continuous measures: WHO-5 questionnaire. WHO-five Well-beeing Index, WHO-5 (Values 0- 100, higher scores mean a better outcome).
Time frame: Week 4 and 8
Difference-in-difference for SCIP
Difference-in-differences for secondary continuous measures: SCIP Screen for Cognitive Impairment in Psychiatry, SCIP (Values 0- 64+, higher scores mean a better outcome)
Time frame: Week 8
Difference-in-difference for COBRA
Difference-in-differences for secondary continuous measures: COBRA Cognitive complaints in bipolar disorder Ratings assessment, COBRA, (Values 0- 48, higher scores mean a worse outcome).
Time frame: Week 8
Difference-in-difference for FAST
Difference-in-differences for secondary continuous measures: FAST Functioning Assessment Short Test, FAST (Values 0 - 72, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for PSQI
Difference-in-differences for secondary continuous measures:PSQI PIttsburgh Sleep Quality Index, PSQI (Values 0 - 21, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for CGI-S
Difference-in-differences for secondary continuous measures: CGI-S Clinical Global Impression Scale - Severity, CGI-S (Values 1 -7, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for CGI-I
Difference-in-differences for secondary continuous measures:CGI-I Clinical Global Impression Scale - Global Improvement CGI- I (Values 1 -7, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for C-SSRS
Difference-in-differences for secondary continuous measures: C-SSRS Columbia-Suicide Severity Rating Scale, C-SSRS (Values 1 - 5, higher scores mean a worse outcome).
Time frame: Week 4 and 8
Difference-in-difference for accumulated benzodiazepine dose
Difference-in-differences for secondary continuous measures: accumulated benzodiazepine dose as diazepam equivalents (DSKP)
Time frame: Up to 8 weeks
Difference-in-difference for time to all-causes discontinuation
Difference-in-differences for secondary continuous measures: for time to all-causes discontinuation
Time frame: Up to 8 weeks
Difference-in-difference for time to all-causes. all-causes study endpoint.
Difference-in-differences for secondary continuous measures: all-causes study endpoint.
Time frame: Up to 8 weeks
Between-group difference in reasons for time to all cause discontinuation.
Between-group difference for the ITT population in reasons for time to all cause discontinuation.
Time frame: Up to 8 weeks
Between-group difference in reasons for treatment expectation.
Between-group difference for the ITT population in reasons for treatment expectation.
Time frame: Up to 8 weeks
Between-group difference in reasons for adverse events.
Between-group difference for the ITT population in reasons for adverse events.
Time frame: Up to 8 weeks
Between-group difference in reasons for serious adverse events.
Between-group difference for the ITT population in reasons for serious adverse events.
Time frame: Up to 8 weeks
Plan to share: No
Started Dec 2022 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.
Of 39 non-industry phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 68 months is above that.
Counting every sponsor, half of 44 studies reached it within 43 months; a quarter within 25 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lithium · Cariprazine